Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Receivables - Net (2021 - 2025)

Historic Receivables - Net for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $1.2 billion.

  • Rxo's Receivables - Net fell 8.15% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year decrease of 8.15%. This contributed to the annual value of $1.2 billion for FY2025, which is 8.15% down from last year.
  • As of Q4 2025, Rxo's Receivables - Net stood at $1.2 billion, which was down 8.15% from $1.1 billion recorded in Q3 2025.
  • Rxo's 5-year Receivables - Net high stood at $1.2 billion for Q4 2024, and its period low was $716.0 million during Q1 2024.
  • Moreover, its 5-year median value for Receivables - Net was $1.0 billion (2021), whereas its average is $960.5 million.
  • In the last 5 years, Rxo's Receivables - Net tumbled by 2223.32% in 2023 and then skyrocketed by 6514.13% in 2024.
  • Rxo's Receivables - Net (Quarter) stood at $1.0 billion in 2021, then fell by 10.89% to $900.0 million in 2022, then dropped by 17.44% to $743.0 million in 2023, then soared by 65.14% to $1.2 billion in 2024, then dropped by 0.08% to $1.2 billion in 2025.
  • Its Receivables - Net was $1.2 billion in Q4 2025, compared to $1.1 billion in Q3 2025 and $1.1 billion in Q2 2025.